Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
 & Lead Plaintiff Deadline - March 27, 2017 - EconoTimes)
Add as a preferred source on Google
NEW YORK, March 23, 2017 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (NASDAQ:RWLK) and certain of its officers, on behalf of a class who purchased ReWalk securities pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rwlk.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
ReWalk is a medical commercial bionic walking assistance system. The company designs, develops, and commercializes exoskeletons for wheelchair-bound individuals.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements in its Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a post market surveillance study. Once this information was made public, ReWalk stock price dropped, causing investors harm.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/rwlk or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
